- Associate Analyst, Argus Research
- Cum Laude Graduate With a Bachelor of Science Degree in Business Administration
At Argus Research, Jasper Hellweg covers growth pharmaceutical, medical technology, and financial technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a bachelor of science degree in business administration with concentrations in entrepreneurship and marketing. Prior to joining Argus, Mr. Hellweg worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report, and Argus' bespoke research on IPOs.
AstraZeneca (AZN) has received a range of new product approvals in recent months, including for multiple oncology drugs and treatments for asthma, autoimmune disease, and chronic heart failure. In addition, it continues to make acquisitions, recently acquiring CinCor Pharma and Neogene Therapeutics, writes Jasper Hellweg, analyst at Argus Research.
Merck & Co. (MRK) performed well in 4Q22. Adjusted EPS came to $1.62, above the consensus of $1.54 per share, and revenue came in at $13.83 billion, beating the consensus by $174 million. We are reiterating our BUY rating, writes Jasper Hellweg, analyst at Argus Research.
Vertex Pharmaceuticals (VRTX) — founded in 1989 in Cambridge, Massachusetts — develops therapies to address cystic fibrosis and other diseases, explains Jasper Hellweg, an analyst with Argus Research, a leading independent Wall Street research firm.
Founded in 1945 and based in Switzerland, Alcon AG (ALC) is a global provider of ophthalmic surgery and vision care products; previously a subsidiary of Novartis AG (NVS), Alcon became an independent company in April, 2019, recalls Jasper Hellweg, an analyst with Argus Research.